ALL WALES MEDICINES STRATEGY GROUP

WEDNESDAY, 10th DECEMBER 2008 COMMENCING 10.30 AM (UNTIL 4.30 PM APPROX) AT THE ANGEL HOTEL, ABERGAVENNY

AGENDA

		Enclosure
1.	Welcome and introduction	
2.	Apologies	
3.	Declarations of interest	
4.	Chairman's report (verbal update)	
5.	Minutes of previous meeting - Matters arising	1/AWMSG/1208
6.	Appraisal 1 – alemtuzumab (MabCampath[®]) Treatment of B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate	2 /AWMSG/1208 Appendices
7.	Appraisal 2 – atazanavir (Reyataz [®]) experienced adults Treatment of human immunodeficiency virus (HIV)-1 infected, antiretroviral treatment experienced adults, in combination with other antiretroviral medicinal products	3 /AWMSG/1208 Appendices
8.	Appraisal 3 – atazanavir (Reyataz[®]) naïve adults Antiretroviral treatment in naïve patients	4 /AWMSG/1208 Appendices
9.	Appraisal 4 – ambrisentan (Volibris [®]) Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional Class II and III, to improve exercise capacity, decrease the symptoms of PAH and delay clinical worsening	5/ AWMSG/1208 Appendices
10.	AWMSG 2002-2008	6/AWMSG/1208
11.	Prioritisation of the AWMSG Medicines Strategy recommendations	7/AWMSG/1208
12.	Update on NHS Industry Forum - Draft minutes of October meeting	8/AWMSG/1208
13.	Update on AWPAG - Draft minutes of October meeting - Update of statin template	9 /AWMSG/1208 10 /AWMSG/1208
14.	BNF Chapter 1 – Gastro-intestinal: Key Messages	11/AWMSG/1208
15.	Saving 1000 Lives Campaign	12 /AWMSG/1208
16.	Welsh Analytical Prescribing Unit (verbal update)	
17.	Papers supplied by Welsh Assembly Government to AWMSG for information or comment:	
	Emergency oxygen use in Adults – British Thoracic Society guidance (for information)	13 /AWMSG/1208

Proposed Medicines Management Target for the Draft Service and Financial Framework Target 14/AWMSG/1208

Date of next AWMSG meeting: Wednesday, 25th February 2009 at The Angel Hotel Abergavenny